ROCKVILLE, Md.--(BUSINESS WIRE)--ABL, Inc., a contract research and manufacturing organization to the biotechnology and pharmaceutical industry, is pleased to announce that its GCLP clinical laboratory team was recently selected to provide sample processing and screening services in support of a Ph II glioblastoma multiforme (GBM) immunotherapy trial for a confidential client.
ABL will conduct sample processing to isolate peripheral blood mononuclear cells (PBMCs), screen subject samples to identify antigen-specific responders and provide long-term sample storage. Subsequent activities may include assay qualification and evaluation of cellular immune responses by IFN? ELISpot, multi-dextramer analysis and Intracellular Cytokine Staining.
Dr. Anthony Cristillo, Director of Clinical Operations for ABL, commented, “We are very excited for the opportunity to apply our scientific and clinical expertise in support of this trial. Immunotherapies hold much promise in the treatment of aggressive cancers such as GBM, and ABL’s diverse platform of immunological methods is uniquely suited towards evaluating the many facets of immune function that can be involved.”
These studies will be conducted in ABL’s newly expanded GCLP-compliant laboratory based in Rockville, MD. The facility provides clients with a comprehensive solution to assess the in vivo impact of vaccines and therapies on a patient’s immune system. Assay development, qualification, and routine testing of human samples are available for:
- ELISpot
- Flow cytometry
- Luminex® multiplexing
- ELISA
- Other immunogenicity platforms
About ABL
ABL, Inc. is a Maryland-based biomedical contract research and manufacturing organization dedicated to advancing vaccines, therapeutics and other biologic products. ABL has extensive experience working with diverse organizations, including bio/pharmaceutical companies and government and academic entities. Notable services include basic research, product design, process and assay development, preclinical studies, clinical immunomonitoring and immunogenicity testing, and Phase I/II cGMP biologics manufacturing. Since 2001, ABL has been a part of the Institut Mérieux, a group of companies dedicated to developing translational science for better patient care globally. For more information on ABL and our services, please visit our website at http://www.ablinc.com/.
Contacts
ABL, Inc.
Andrew Arrage
Vice President, Business Development
301-816-5209
andrew.arrage@ablinc.com
Help employers find you! Check out all the jobs and post your resume.
